Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
AptarGroup, Inc. Common Stock
(NY:
ATR
)
123.25
+0.50 (+0.41%)
Official Closing Price
Updated: 7:00 PM EST, Dec 26, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about AptarGroup, Inc. Common Stock
< Previous
1
2
3
4
Next >
Aptar’s Bidose Nasal System Delivers CARDAMYST™ (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT)
December 17, 2025
From
Aptar Group, Inc.
Via
Business Wire
Aptar Named One of America’s Most Responsible Companies by Newsweek for the Seventh Consecutive Year
December 04, 2025
From
AptarGroup, Inc.
Via
Business Wire
Aptar to Present at Jefferies Global Healthcare Conference on November 19, 2025
November 11, 2025
From
AptarGroup, Inc.
Via
Business Wire
Aptar Reports Third Quarter 2025 Results
October 30, 2025
From
AptarGroup, Inc.
Via
Business Wire
Aptar Digital Health Announces FDA 510(k) Clearance for HeroTracker® Sense, a Connected Add-On Device for Metered-Dose Inhalers
October 16, 2025
From
Aptar Digital Health
Via
Business Wire
Aptar Named Among Top 100 of the ‘World’s Top Companies for Women 2025’ by Forbes
October 15, 2025
From
AptarGroup, Inc.
Via
Business Wire
Aptar Increases Quarterly Dividend by Nearly 7% Signaling Continued Momentum and Long-Term Strength
September 08, 2025
From
AptarGroup, Inc.
Via
Business Wire
Aptar Announces 2025 Investor Day
September 04, 2025
From
AptarGroup, Inc.
Via
Business Wire
Aptar Reports Second Quarter 2025 Results
July 31, 2025
From
AptarGroup, Inc.
Via
Business Wire
Aptar Declares Quarterly Dividend
July 10, 2025
From
AptarGroup, Inc.
Via
Business Wire
Aptar Named One of the World’s Most Sustainable Companies by TIME for Second Consecutive Year
June 25, 2025
From
AptarGroup, Inc.
Via
Business Wire
Aptar to Participate in Upcoming Investor Conferences
June 02, 2025
From
AptarGroup, Inc.
Via
Business Wire
Aptar Releases 2024 Corporate Sustainability Report
May 29, 2025
From
AptarGroup, Inc.
Via
Business Wire
Aptar Reports First Quarter 2025 Results
May 01, 2025
From
AptarGroup, Inc.
Via
Business Wire
Aptar Declares Quarterly Dividend
April 17, 2025
From
AptarGroup, Inc.
Via
Business Wire
Aptar Announces Clinical Validation Study to Accelerate US FDA Approval of SmartTrack™ In-Vitro-in-Silico Platform for Pressurized Metered-Dose Inhalers
April 16, 2025
From
AptarGroup, Inc.
Via
Business Wire
Aptar Receives Platinum Rating from EcoVadis for the Fifth Consecutive Year
April 15, 2025
From
AptarGroup, Inc.
Via
Business Wire
Aptar Named One of Barron’s 100 Most Sustainable U.S. Companies for the Seventh Consecutive Year
March 27, 2025
From
AptarGroup, Inc.
Via
Business Wire
Aptar Recognized with Prestigious 'A' Score on the CDP Climate Change Assessment
March 20, 2025
From
AptarGroup, Inc.
Via
Business Wire
Aptar Reports Fourth Quarter and Annual 2024 Results
February 06, 2025
From
AptarGroup, Inc.
Via
Business Wire
Aptar Declares Quarterly Dividend and Announces 2025 Annual Meeting Details
January 23, 2025
From
AptarGroup, Inc.
Via
Business Wire
Aptar Named One of America’s Most Responsible Companies by Newsweek for the Sixth Consecutive Year
January 14, 2025
From
AptarGroup, Inc.
Via
Business Wire
Aptar Announces 2025 Quarterly Conference Call Dates
January 08, 2025
From
Aptar
Via
Business Wire
Aptar to Present at 43rd Annual J.P. Morgan Healthcare Conference on January 16, 2025
January 06, 2025
From
AptarGroup, Inc.
Via
Business Wire
Aptar Named Among Top 50 of the ‘World’s Top Companies for Women 2024’ by Forbes
November 13, 2024
From
AptarGroup, Inc.
Via
Business Wire
Aptar Reports Third Quarter 2024 Results
October 24, 2024
From
AptarGroup, Inc.
Via
Business Wire
Aptar Awarded Federal Government Contract to Advance Novel Sterilization Technology for Medical Devices
October 22, 2024
From
AptarGroup, Inc.
Via
Business Wire
Aptar Announces New $500 Million Share Repurchase Authorization and Declares Quarterly Dividend
October 10, 2024
From
AptarGroup, Inc.
Via
Business Wire
Aptar’s N-Sorb Nitrosamine Mitigation Solution Accepted to US FDA’s Emerging Technology Program
September 23, 2024
From
AptarGroup, Inc.
Via
Business Wire
Aptar’s Nasal Unidose System to Deliver neffy® (epinephrine nasal spray), the First and Only FDA-Approved Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
August 15, 2024
From
AptarGroup, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit